• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 

Sofinnova Partners

Sofinnova's Cerenis in €226m IPO

French biotech company raises €53.4m as part of listing

  • Exits
  • 26 March 2015
Sofinnova et al. invest $42m in Green Biologics

Company has also secured $34m in debt alongside capital increase

  • Expansion
  • 29 January 2015
VC-backed Ascendis raises $108m in IPO

Listing priced at $18 per share

  • Nordics
  • 29 January 2015
Ascendis completes $60m series-D

A total of seven investors comitted capital to the round

  • Expansion
  • 02 December 2014
VC-backed ProQR raises $97.5m in IPO

Listed Dutch biotech develops drugs designed for the treatment of genetic disorders

  • Benelux
  • 19 September 2014
Richter joins Sofinnova from Novo Seeds

Former investment director joins after seven years in Denmark

  • GPs
  • 02 September 2014
VC-backed ProQR files for $75m IPO

Sofinnova is company's largest shareholder

  • Benelux
  • 18 August 2014
Auris' delayed IPO lists below initial price range

Number of shares on offer increased by more than 35% but price almost halved

  • DACH
  • 08 August 2014
Sofinnova-backed Auris announces price range

Float expected to be worth between £69-82m

  • DACH
  • 23 July 2014
Deal in focus: Capricorn et al. invest €36m in Avantium
Deal in focus: Capricorn et al. invest €36m in Avantium

Company attracted funding from VC backers as well as corporates

  • Benelux
  • 30 June 2014
VC-backed Pixium floats with €100m market cap

Company sold 4.2 million shares at 828 euro cents apiece

  • France
  • 25 June 2014
Sofinnova et al. inject €36m into Avantium

Capital injection is from consortium of VCs and strategic trade players

  • Expansion
  • 05 June 2014
VC-backed Pixium plans flotation

Company could raise up to €36.6m in IPO

  • France
  • 04 June 2014
SEP's Metaforic sold to VC-backed Inside Secure for $11.6m

Buyer backed by Sofinnova and Gimv

  • Exits
  • 09 April 2014
VC-backed McPhy raises €32m in IPO

Offer oversubscribed by 8.6x

  • France
  • 26 March 2014
EdRip, Sofinnova lead €18m round for Inotrem

Biomed Invest and Inserm Transfert Initiative also take part

  • France
  • 14 March 2014
VC-backed McPhy to float on Euronext

Company could raise up to €24.2m

  • France
  • 07 March 2014
Crescendo Biologics secures £17.5m series-A

UK biotech Crescendo Biologics has raised ТЃ17.5m in its series-A funding round from Imperial Innovations, Astellas Venture Management (AVM) and existing investor Sofinnova Partners.

  • UK / Ireland
  • 18 December 2013
Sofinnova leads £15m round for Green Biologics

Sofinnova Partners has led a ТЃ15.4m series-B funding round for Green Biologics, a UK-based chemicals producer, alongside Hong Kong-based Swire Pacific and several existing investors.

  • UK / Ireland
  • 02 December 2013
Sofinnova leads £2.4m round for CelluComp

Sofinnova Partners has led a ТЃ2.4m funding round for CelluComp, a Scottish sustainable materials company, with participation from the Scottish Investment Bank (SIB).

  • UK / Ireland
  • 29 November 2013
Sofinnova leads €15m round for Pixium

Sofinnova Partners has led a €15m extension of Pixium Vision’s two-part series-A round alongside BPI France and existing investors Omnes Capital and Abingworth Management.

  • France
  • 25 November 2013
Sofinnova Partners et al. sell EOS for up to €310m

Sofinnova Partners, Aescap Venture and Principia have sold Milan-based cancer therapeutics firm Ethical Oncology Science (EOS) to Clovis Oncology via an agreement that could see the firm fetch up to €310m.

  • Southern Europe
  • 20 November 2013
Mission Therapeutics raises £20m

A syndicate of new and existing venture capital investors has injected ТЃ20m into UK-based biotech Mission Therapeutics as part of its series-B funding round.

  • UK / Ireland
  • 18 November 2013
Sofinnova, Forbion lead €20m round for Hookipa

A consortium of investors led by Sofinnova Partners and Forbion Capital Partners has invested €20m in a series-B funding round for Austria-based Hookipa Biotech.

  • DACH
  • 05 November 2013
234
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013